Heilongjiang ZBD Pharmaceutical Co Ltd (603567) - Total Liabilities
Based on the latest financial reports, Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has total liabilities worth CN¥4.51 Billion CNY (≈ $659.83 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Heilongjiang ZBD Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Heilongjiang ZBD Pharmaceutical Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Heilongjiang ZBD Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Heilongjiang ZBD Pharmaceutical Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Heilongjiang ZBD Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Heilongjiang ZBD Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Life Healthcare
JSE:LHC
|
South Africa | ZAC11.49 Billion |
|
Corticeira Amorim
LS:COR
|
Portugal | €491.25 Million |
|
Clean Science and Technology Limited
NSE:CLEAN
|
India | Rs1.84 Billion |
|
Ta Ya Electric Wire & Cable Co., Ltd.
TW:1609
|
Taiwan | NT$43.28 Billion |
|
Aoyuan Beauty Valley Technology Co Ltd
SHE:000615
|
China | CN¥611.79 Million |
|
WEB Travel Group Ltd
AU:WEB
|
Australia | AU$961.70 Million |
|
Rastar Group
SHE:300043
|
China | CN¥2.51 Billion |
|
Hiconics Drive Tech Co
SHE:300048
|
China | CN¥3.06 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Heilongjiang ZBD Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 603567 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Heilongjiang ZBD Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total liabilities of Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥4.42 Billion ≈ $647.01 Million |
-0.08% |
| 2023-12-31 | CN¥4.43 Billion ≈ $647.55 Million |
-3.14% |
| 2022-12-31 | CN¥4.57 Billion ≈ $668.53 Million |
+2.55% |
| 2021-12-31 | CN¥4.45 Billion ≈ $651.89 Million |
-5.84% |
| 2020-12-31 | CN¥4.73 Billion ≈ $692.32 Million |
+25.55% |
| 2019-12-31 | CN¥3.77 Billion ≈ $551.45 Million |
+17.81% |
| 2018-12-31 | CN¥3.20 Billion ≈ $468.06 Million |
+44.94% |
| 2017-12-31 | CN¥2.21 Billion ≈ $322.94 Million |
+4.48% |
| 2016-12-31 | CN¥2.11 Billion ≈ $309.10 Million |
+7.33% |
| 2015-12-31 | CN¥1.97 Billion ≈ $288.00 Million |
+37.49% |
| 2014-12-31 | CN¥1.43 Billion ≈ $209.47 Million |
-4.83% |
| 2013-12-31 | CN¥1.50 Billion ≈ $220.09 Million |
+86.07% |
| 2012-12-31 | CN¥808.30 Million ≈ $118.28 Million |
+56.43% |
| 2011-12-31 | CN¥516.70 Million ≈ $75.61 Million |
-- |
About Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.